{"id":36940,"date":"2019-01-17T08:00:00","date_gmt":"2019-01-17T06:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&#038;p=36940"},"modified":"2023-09-06T18:07:26","modified_gmt":"2023-09-06T16:07:26","slug":"ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/","title":{"rendered":"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019"},"content":{"rendered":"<p align=\"center\"><b>S\u00e9curit\u00e9, tol\u00e9rance et pharmacodynamique de BoNT-E<\/b><br \/>\n<b>d\u00e9montr\u00e9es dans le cadre de l\u2019\u00e9tude de phase I<\/b><b>1<\/b><br \/>\n<b>Paris (France), 17 janvier 2019 \u2013 <\/b>Les r\u00e9sultats de la premi\u00e8re \u00e9tude chez l\u2019homme d\u2019une neurotoxine recombinante seront pr\u00e9sent\u00e9s lors de la conf\u00e9rence internationale TOXINS 2019 qui se tiendra \u00e0 Copenhague (Danemark). La neurotoxine botulique recombinante de s\u00e9rotype E (rBoNT-E) d\u2019Ipsen a \u00e9t\u00e9 \u00e9tudi\u00e9e dans le cadre d\u2019une \u00e9tude de phase I qui a caract\u00e9ris\u00e9 son profil de s\u00e9curit\u00e9 et de tol\u00e9rance chez des volontaires sains1. L\u2019\u00e9tude a \u00e9galement d\u00e9montr\u00e9 qu\u2019elle agissait plus rapidement et moins longtemps que les neurotoxines botuliques de type A existantes, et que son pic d\u2019action \u00e9tait atteint plus rapidement. D\u2019autres \u00e9tudes seront men\u00e9es pour \u00e9tablir les utilisations esth\u00e9tiques et th\u00e9rapeutiques potentielles de ce traitement exp\u00e9rimental.<br \/>\n<em>\u00ab L\u2019application des techniques recombinantes pour cr\u00e9er de nouveaux m\u00e9dicaments \u00e0 base de toxine botulique ayant des d\u00e9lais et des dur\u00e9es d\u2019action diff\u00e9rents va potentiellement permettre aux praticiens de choisir la neurotoxine adapt\u00e9e \u00e0 chaque patient, ce qui n\u2019est pas possible aujourd\u2019hui,<\/em> \u00bb a d\u00e9clar\u00e9 <b>Philippe Picaut, Vice-Pr\u00e9sident Senior, Recherche &amp; D\u00e9veloppement pour les Neurosciences chez Ipsen<\/b>.<br \/>\nLes neurotoxines botuliques sont des prot\u00e9ines naturelles (produites par les bact\u00e9ries <em>Clostridium<\/em>) dont la d\u00e9couverte remonte au 19\u00e8me si\u00e8cle. Elles sont class\u00e9es en sept s\u00e9rotypes (A-G), la majorit\u00e9 des neurotoxines botuliques commercialis\u00e9es \u00e9tant de s\u00e9rotype A. Elles sont utilis\u00e9es dans de multiples conditions apr\u00e8s une injection dans les muscles squelettiques (dystonie cervicale, spasme h\u00e9mifacial, bl\u00e9pharospasme, spasticit\u00e9 chez l\u2019adulte et chez l\u2019enfant, esth\u00e9tique) ; muscles lisses (hyperactivit\u00e9 neurog\u00e8ne du d\u00e9trusor, hyperactivit\u00e9 de la vessie idiopathique) ou hyperfonctionnement des glandes exocrines (sialorrh\u00e9e, hyperhidrose axillaire).<br \/>\n<b>Le Docteur Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif, Recherche &amp; D\u00e9veloppement et Chief Scientific Officer, Ipsen <\/b>a d\u00e9clar\u00e9 : <em>\u00ab La recherche sur les neurotoxines progresse \u00e0 un rythme sans pr\u00e9c\u00e9dent. Ipsen \u00e9labore des solutions th\u00e9rapeutiques et esth\u00e9tiques innovantes qui aident les patients \u00e0 reprendre le contr\u00f4le de leur vie et est \u00e0 l\u2019avant-garde de cette transformation \u00bb.<\/em><br \/>\nIpsen pr\u00e9sentera 50 posters lors de la conf\u00e9rence TOXINS 2019 \u00e0 Copenhague, notamment :<\/p>\n<ul>\n<li style=\"margin-bottom:3px\">Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA (Dysport); Pons et al.<\/li>\n<li style=\"margin-bottom:3px\">New modified recombinant botulinum neurotoxin type F with enhanced potency; Burgina et al.<\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556],"tags":[],"class_list":["post-36940","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-06T16:07:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019\",\"datePublished\":\"2019-01-17T06:00:00+00:00\",\"dateModified\":\"2023-09-06T16:07:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\"},\"wordCount\":448,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\",\"name\":\"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2019-01-17T06:00:00+00:00\",\"dateModified\":\"2023-09-06T16:07:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/","og_site_name":"Global","article_modified_time":"2023-09-06T16:07:26+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019","datePublished":"2019-01-17T06:00:00+00:00","dateModified":"2023-09-06T16:07:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/"},"wordCount":448,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/","name":"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2019-01-17T06:00:00+00:00","dateModified":"2023-09-06T16:07:26+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/Yjg5NGQzZmMtY2I4Yy00OWY4LThhODgtNDkwZThlMTQ0NjU5LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-les-resultats-de-la-premiere-etude-sur-lhomme-dune-neurotoxine-recombinante-a-action-rapide-rbont-e-au-congres-toxins-2019\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen pr\u00e9sente les r\u00e9sultats de la premi\u00e8re \u00e9tude sur l\u2019homme d\u2019une neurotoxine recombinante \u00e0 action rapide (rBoNT-E) au Congr\u00e8s TOXINS 2019"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36940\/revisions"}],"predecessor-version":[{"id":36944,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36940\/revisions\/36944"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}